As many as nine transfer orders were issued earlier this week, of which five are related to top officials in the CDSCO. While four deputy drug controllers (DDC) are transferred from this headquarter to different zonal offices, one DDC with additional charge of west zone is being brought back to the New Delhi headquarters. The transfer order, issued on January 27, has been reviewed by Business Standard.
Sources suggest the move comes in the wake of a recent corruption case in Hyderabad where a DDC was allegedly found accepting a bribe from a blood bank. However, DCGI G N Singh said the transfers are “isolated from any such case”. “We want to bring transparency and accountability into the system. We realised that the position of deputy drug controller is very sensitive and they need rotation, which will also give them more exposure,” Singh said.
The move assumes significance because of the events presently surrounding the drug manufacturing industry. As CDSCO has been in the spotlight for its lack of resources, inadequate monitoring of clinical trials and approval of new drugs, of late it has also been criticised for its failure to monitor drug manufacturing practices effectively.
The latest to come under the scanner is Ranbaxy Laboratories, whose India manufactured drugs are barred from the US. While DCGI has ordered inspection of the company’s Toansa facility, files related to various show-cause notices served to Ranbaxy and others were being handled by DDCs so far.
The four DDCs to be moved from the CDSCO headquarter are K Bangarurajan, A K Pradhan, S P Shani and S E Reddy.
Singh said such rotations would now be conducted every three years on an average.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)